NIOSH issues July 17, 2025 notice adding three hazardous drugs (MSHI) to Table 1 of the 2024 hazardous drug list

NIOSH posted a notice dated July 17, 2025 stating that three drugs with manufacturer’s special handling information (MSHI) are considered included in Table 1 of the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024: datopotamab deruxtecan (Datroway®), treosulfan (Grafapex™), and telisotuzumab vedotin (Emrelis™). Healthcare organizations and entities aligning hazardous drug handling programs (e.g., under USP <800>) should evaluate whether these agents are handled onsite and update inventories, risk assessments, SOPs, training, engineering controls/PPE, labeling, and waste procedures accordingly.